In vitro quality assessment of myogenic stem cells in multiple patient groups with confirmed skeletal muscle atrophy to study their potential for autologous stem cell therapy

• Conditions: cachexie; muscle atrophy; muscle wasting; 10028302

• Registration Number: NL-OMON56403
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Patient group: cachexia - Diagnosed with non-small cell lung cancer (NSCLC),
stage 3-4 - Diagnosed with cachexia (>5% unintentional body weight loss in past
six months) - Age 50-60 and 60-70 - Written informed consent Patient group:
muscle impaired elderly - Scheduled for knee-, back- or hip surgery - Age 60-70
and 70-80y - Written informed consent Controls - Scheduled for knee-, back- or
hip surgery - Age 50-60, 60-70 and 70-80 - Written informed consent

Exclusion Criteria

- No informed consent
- Suffering from a muscular dystrophy or other disease known to affect muscle
morphology or function
- Have a weekly alcohol intake of >= 35 units (men) or >= 24 units (women)
- Ongoing participation in other intervention clinical trials
- Major surgery within 4 weeks of the visit
- Patients unable and/or unwilling to comply with treatment and study
instructions
- Any other factor that in the opinion of the investigator excludes the patient
from the study

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• Immunophenotype characterization of mesoangioblasts (i.e. number of the<br /><br>correct cells isolated from a muscle biopsy) by Alkaline phosphatase staining<br /><br>to determine stemness (>50%); and cell sorting via magnetic-activated cell<br /><br>sorting (MACS) and/or fluorescent-activated cell sorting (FACS) depending on<br /><br>surface antigens (>50%) • Proliferation rate of mesoangioblasts in vitro<br /><br>(population doubling level: >2 every 3-4 days) • Muscle regenerative capacity<br /><br>of mesoangioblasts in terms of the formation of multinucleated mature myotubes<br /><br>(>25% of total nuclei).</p><br>